1. 1015. Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis. (31st December 2020) Authors: Dunn, Keith; Huang, Yangxin; Baugh, Bryan; Bejou, Nika; Luo, Donghan; Campbell, Jennifer; Anderson, David Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging. (26th November 2018) Authors: Spinner, Christoph D; Rashbaum, Bruce; Mcdonald, Cheryl; Mussini, Cristina; Luo, Donghan; Jezorwski, John; Brown, Kimberley; Wong, Eric Y Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study. (27th December 2019) Authors: Huhn, Gregory D; Crofoot, Gordon; Ramgopal, Moti; Gathe, Joseph; Bolan, Robert; Luo, Donghan; Simonson, Richard Bruce; Nettles, Richard E; Benson, Carmela; Dunn, Keith Journal: Clinical infectious diseases Issue: Volume 71:Number 12(2020) Page Start: 3110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study. Issue 1 (2nd January 2019) Authors: Rashbaum, Bruce; Spinner, Christoph D.; McDonald, Cheryl; Mussini, Cristina; Jezorwski, John; Luo, Donghan; Van Landuyt, Erika; Brown, Kimberley; Wong, Eric Y. Journal: HIV research & clinical practice Issue: Volume 20:Issue 1(2019) Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment‐naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis. Issue 3 (15th August 2022) Authors: Dunn, Keith; Bushen, Jennifer; Luo, Donghan; Cai, Jiyun; Simonson, Richard Bruce; Anderson, David Journal: HIV medicine Issue: Volume 24:Issue 3(2023) Page Start: 279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. Issue 1 (December 2017) Authors: Bourgeois, Stefan; Van Vlierberghe, Hans; Moreno, Christophe; Orlent, Hans; Nevens, Frederik; Arastéh, Keikawus; Horsmans, Yves; Schattenberg, Jörn; Buggisch, Peter; Francque, Sven; Vijgen, Leen; Kakuda, Thomas; Hoeben, Eva; Luo, Donghan; Vandebosch, An; Jacquemyn, Bert; Van Remoortere, Pieter; V... Journal: BMC gastroenterology Issue: Volume 17:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies. Issue 5 (2nd November 2017) Authors: Lathouwers, Erkki; Wong, Eric Y.; Luo, Donghan; Seyedkazemi, Sareh; De Meyer, Sandra; Brown, Kimberley Journal: HIV clinical trials Issue: Volume 18:Issue 5/6(2017) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies. Issue 5 (2nd November 2017) Authors: Lathouwers, Erkki; Wong, Eric Y.; Luo, Donghan; Seyedkazemi, Sareh; De Meyer, Sandra; Brown, Kimberley Journal: HIV clinical trials Issue: Volume 18:Issue 5/6(2017) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. (April 2022) Authors: Dunn, Keith; Baugh, Bryan; Bejou, Nika; Luo, Donghan; Campbell, Jennifer; Seyedkazemi, Sareh; Anderson, David Journal: Journal of the International Association of Providers of AIDS Care Issue: Volume 21(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. (11th November 2014) Authors: Berg, Thomas; Andreone, Pietro; Pol, Stanislas; Roberts, Stuart; Younossi, Zobair; Diago, Moises; Lawitz, Eric J.; Focaccia, Roberto; Foster, Graham R.; Horban, Andrzej; Lonjon‐Domanec, Isabelle; DeMasi, Ralph; Picchio, Gaston; Luo, Donghan; De Meyer, Sandra; Zeuzem, Stefan Journal: Liver international Issue: Volume 35:Number 2(2015:Feb.) Page Start: 448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗